[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100560974":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":26,"locations":32,"responsibleParty":52,"collaborators":55,"id":57,"slug":20,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":58,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":20,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":76,"overallStatus":35,"whyStopped":20,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"University of Cambridge","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Study cohort","EXPERIMENTAL","All patient's enrolled in the study will undergo an 18F-FET-PET",[13],"Diagnostic Test: 18F-Fluoro-ethyl-tyrosine (FET) PET",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DIAGNOSTIC_TEST","18F-Fluoro-ethyl-tyrosine (FET) PET","18F-Fluoro-ethyl-tyrosine PET study of the pituitary",[9],null,[22],{"name":23,"affiliation":24,"role":25},"Mark Gurnell, MD, PhD","Cambridge University Hospitals NHS Foundation Trust","PRINCIPAL_INVESTIGATOR",[27],{"name":28,"role":29,"phone":30,"phoneExt":20,"email":31},"James MacFarlane","CONTACT","01223 250882","jm2267@medschl.cam.ac.uk",[33],{"facility":34,"status":35,"city":36,"state":37,"zip":38,"country":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"Cambridge University Hospitals","RECRUITING","Cambridge","Cambridgeshire","CB2 0QQ","United Kingdom",{"type":41,"coordinates":42},"Point",[43,44],0.11667,52.2,{"lat":44,"lon":43},[47,51],{"name":48,"role":29,"phone":49,"phoneExt":20,"email":50},"Mark Gurnell, PhD FRCP","+44-1223-245151","mark.gurnell2@nhs.net",{"name":48,"role":25,"phone":20,"phoneExt":20,"email":20},{"type":25,"investigatorFullName":53,"investigatorTitle":54,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Professor Mark Gurnell","Professor of Clinical Endocrinology",[56],{"name":24,"class":6},"100560974",false,"NCT06584123","Molecular Pituitary Imaging Using 18F-FET PET","Exploring the Potential for 18F-fluoro-ethyl-tyrosine (18F-FET) to Enable Wider Access to Molecular Imaging for Patients With Pituitary Adenomas (FET-pit-PET Study)","FET-pit-PET","Inclusion criteria\n\n* Participant is willing and able to give informed consent for participation in the study\n* Male or female, age 18 or above\n* Presence of pituitary adenoma suspected on the basis of clinical\u002Fbiochemical and\u002For radiological findings\n* Previous 11C-Met-PET\u002FCT\n\nExclusion criteria\n\n* Inability to give informed consent\n* Pregnancy or suspected pregnancy\n* Inability to lie supine for 30-60 minutes\n* Patient body habitus above scanner dimensions\n* Known allergy to intravenous radiographic contrast agents","ALL","18 Years","100 Years",{"count":68,"type":69},20,"ESTIMATED","INTERVENTIONAL",[72],"NA","The goal of this single centre pilot study is to explore whether 18F-fluoro-ethyl-tyrosine PET (FET-PET) yields comparable findings to 11C-methionine PET (Met-PET) for the localisation of pituitary tumours.",[75],"Pituitary Adenoma",[77,78,79],"Molecular pituitary imaging","Functional pituitary imaging","18F-FET PET","2026-01-05",{"date":82,"type":83},"2026-01-06","ACTUAL",{"date":85,"type":83},"2024-09-03",{"date":87,"type":69},"2026-12-31",{"name":5,"class":6},1]